Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IRAK1 shRNA
- Development stage
- Preclinical
- Lead developer
- University of Kansas Medical Center
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal, Intratumoral
01
Overview
IRAK1 shRNA is a gene-silencing therapeutic candidate designed to knock down the expression of interleukin-1 receptor-associated kinase 1 (IRAK1). IRAK1 is a critical mediator in the Toll-like receptor (TLR) and Interleukin-1 receptor (IL-1R) signaling pathways, which are highly activated in cisplatin-resistant ovarian cancer and cancer stem cell (CSC) populations. By utilizing short hairpin RNA (shRNA) to reduce IRAK1 levels, this approach aims to impair CSC-enriched spheroid growth and orthotopic tumor progression. Research conducted at the University of Kansas Medical Center indicates that IRAK1 knockdown leads to the downregulation of stemness-related genes, including STAT3, MYC, and NOTCH, as well as a reduction in the cisplatin efflux transporter ABCC1. This modality is being explored as a potential strategy to overcome chemoresistance and recurrence in advanced ovarian cancer.
- Other names
- shIRAK1shIRAK-1shIRAK 1IRAK1-specific shRNAIRAK-1-specific shRNAIRAK 1-specific shRNA
02
Targets
IRAK1 (Interleukin-1 receptor-associated kinase 1)
Beyond the preview
Go deeper on IRAK1 shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IRAK1 shRNA.